The number of patients combining Plavix and PPI therapy is decreasing, study shows
A new study reveals that there has been a significant reduction in the number of individuals who buy Plavix and combine it with the use of a proton pump inhibitor (PPI).
A new study that will be presented on April 29 at the 23rd annual meeting of the Academy of Managed Care Pharmacy reveals that there has been a significant reduction in the number of individuals who buy Plavix and combine it with the use of a proton pump inhibitor (PPI). Although both medications are safe and efficient when used on their own, taking them simultaneously may be harmful.
Pharmacy benefit management company Prime Therapeutics recently sent out a letter to healthcare providers notifying them of this fact, which resulted in a substantially lower number of patients who combined Plavix with a PPI.
"When patients or physicians are unaware of how drugs can react with one another, they are potentially putting themselves at risk for greater harm and health complications," said Patrick Gleason, director of clinical outcomes assessment for Prime Therapeutics.
He added that this study shows that insurers and pharmacy benefit managers may partner successfully to increase patient safety through simple, cost-effective tactics that can prevent the combination of Plavix and PPI.
Individuals who buy Plavix have observed firsthand its positive effects in helping to reduce the risk of stroke and heart attack. The safe use of this medication can enable them to maintain good health for many years to come.
|
